News & Updates
Showing Gastroenterology articles
Showing

Traditional dietary advice most preferred for IBS
Traditional dietary advice, gluten-free diet, and low FODMAP diet are all effective dietary approaches to reducing symptoms in patients with irritable bowel symptom (IBS), but traditional dietary advice is the pick of the bunch in terms of cost and convenience, according to a team of UK-based researchers.
Traditional dietary advice most preferred for IBS
07 Mar 2022
Universal HCV screening in pregnancy: A step toward reducing transmission?
Universal screening for hepatitis C virus (HCV) in pregnant individuals resulted in improved detection and a potential reduction in perinatal transmission, according to a study presented at CROI 2022.
Universal HCV screening in pregnancy: A step toward reducing transmission?
01 Mar 2022
Allopurinol use, dose escalation do not increase mortality in gout patients with CKD
In patients with gout and concurrent chronic kidney disease (CKD), the risk of mortality does not seem to increase with initiation of allopurinol, achieving target serum urate (SU) level with allopurinol, or treatment dose escalation, a study has shown.
Allopurinol use, dose escalation do not increase mortality in gout patients with CKD
01 Mar 2022
KEYNOTE-394 a win for Asians with advanced HCC
Combining pembrolizumab with best supportive care (BSC) improved survival and response when used as second-line therapy in Asians with advanced hepatocellular carcinoma (HCC).
KEYNOTE-394 a win for Asians with advanced HCC
01 Mar 2022
STRIDE regimen boosts OS in unresectable HCC
The addition of tremelimumab to durvalumab (STRIDE regimen) in the first-line setting improved overall survival (OS) compared with sorafenib in patients with advanced unresectable hepatocellular carcinoma (HCC), according to results of the phase III HIMALAYA trial.
STRIDE regimen boosts OS in unresectable HCC
25 Feb 2022
Lenvatinib-TACE combo a new first-line treatment alternative for advanced liver cancer?
In individuals with advanced hepatocellular carcinoma (HCC), the combination of transarterial chemoembolization (TACE) and lenvatinib as first-line treatment led to improved survival outcomes as opposed to lenvatinib monotherapy, according to findings of the phase III LAUNCH* trial.



